Transcenta will receive an upfront payment of RMB 10 million and will be eligible for milestone payments upon the achievement ...
First-in-human study will assess the safety and tolerability of the ultra-long-acting oral peptide in healthy adults and ...
Commemorating BGI Group's 27th anniversary, BGI Genomics today introduced its Digital Life Twin framework alongside an ...
PNOC035 is conducted by the Pediatric Neuro-Oncology Consortium (PNOC), an open-label, multi-center platform study. In Arm A, patients receive oral, once-daily paxalisib in combination with ...
Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth quarter of 2026; Financing led ...
A graphic illustration of CordenPharma’s new 11,000 m² sterile manufacturing facility in Caponago, Italy, increasing the site ...
AC-201 is a novel, highly selective and potent oral small-molecule inhibitor of TYK2/JAK1 that binds to the pseudo kinase ...
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was ...
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has initiated a U.S. Phase I study of ASC36 oral tablets ...
The first Phase 3 study of SKB378/WIN378 has been initiated evaluating two twice-yearly doses. A second Phase 3 trial is ...
HIMSS26 APAC a flagship digital health event for the Asia-Pacific region at Marina Bay Sands Expo and Convention Centre in ...
The IND clearance marks the transition of the first-in-class new drug from preclinical research into clinical development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results